Jacobs & Co. CA Lowers Holdings in Pfizer Inc. $PFE

Jacobs & Co. CA decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 15.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 155,500 shares of the biopharmaceutical company’s stock after selling 28,066 shares during the quarter. Jacobs & Co. CA’s holdings in Pfizer were worth $3,871,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in Pfizer in the second quarter worth about $2,270,157,000. Franklin Resources Inc. increased its position in Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after purchasing an additional 5,662,309 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline — Pfizer reported positive topline results from the Phase 3 TALAPRO-3 study showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer, a meaningful late‑stage win that could expand a high‑value oncology franchise. TALAPRO-3 Topline
• Positive Sentiment: Mid‑stage breast cancer data supports pipeline — Pfizer’s Phase 2 FOURLIGHT‑1 trial of atirmociclib met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, cutting risk of progression and strengthening Pfizer’s bid to follow on from CDK4/6 leaders (Ibrance, etc.). This readout is being positioned as a key oncology catalyst. Atirmociclib Phase 2 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — HSBC raised its price target to $32 and moved to a buy rating, citing upside to Pfizer’s valuation; that upgrade has drawn investor attention and provided near‑term support. HSBC Upgrade
• Neutral Sentiment: Early‑stage liver program advanced — Pfizer updated progress on a Phase 1 PF‑07328948 liver study, which modestly supports the pipeline but is an early, lower‑visibility catalyst. PF‑07328948 Liver Study
• Neutral Sentiment: Public commentary and investor interest — Media/columnist coverage (including Jim Cramer) and various valuation pieces have increased attention on PFE, driving trading volume but not a clear directional catalyst. Cramer & Media Coverage
• Negative Sentiment: Program trimming: early‑stage melanoma study ended — Pfizer discontinued an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and tempers the otherwise bullish pipeline narrative. Melanoma Study Stop
• Negative Sentiment: Industry pricing scrutiny — A Reuters/analysis piece on TrumpRx highlights continued political scrutiny of U.S. drug prices; broader policy and pricing headlines can pressure large pharma multiples and investor sentiment for companies like Pfizer. TrumpRx Pricing Analysis

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Barclays assumed coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Bank of America reduced their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Finally, Morgan Stanley set a $27.00 price objective on Pfizer and gave the stock a “positive” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.14.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE opened at $27.33 on Thursday. The business’s 50-day moving average is $26.61 and its 200 day moving average is $25.57. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The firm has a market capitalization of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The company’s revenue was down 1.2% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.